| miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response B Mateescu, L Batista, M Cardon, T Gruosso, Y De Feraudy, O Mariani, ... Nature medicine 17 (12), 1627-1635, 2011 | 520 | 2011 |
| Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers T Gruosso, M Gigoux, VSK Manem, N Bertos, D Zuo, I Perlitch, SMI Saleh, ... The Journal of clinical investigation 129 (4), 1785-1800, 2019 | 386 | 2019 |
| Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression O Maller, AP Drain, AS Barrett, S Borgquist, B Ruffell, I Zakharevich, ... Nature Materials, 1-12, 2020 | 207 | 2020 |
| Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning F Klauschen, KR Müller, A Binder, M Bockmayr, M Hägele, P Seegerer, ... Seminars in cancer biology 52, 151-157, 2018 | 176 | 2018 |
| Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach Y Bareche, L Buisseret, T Gruosso, E Girard, D Venet, F Dupont, ... JNCI: Journal of the National Cancer Institute 112 (7), 708-719, 2020 | 173 | 2020 |
| Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ... NPJ breast cancer 6 (1), 1-16, 2020 | 166 | 2020 |
| Chronic oxidative stress promotes H2 AX protein degradation and enhances chemosensitivity in breast cancer patients T Gruosso, V Mieulet, M Cardon, B Bourachot, Y Kieffer, F Devun, ... EMBO molecular medicine 8 (5), 527-549, 2016 | 163 | 2016 |
| Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer X Li, T Gruosso, D Zuo, A Omeroglu, S Meterissian, MC Guiot, A Salazar, ... Proceedings of the National Academy of Sciences 116 (9), 3678-3687, 2019 | 140 | 2019 |
| Inhibition of the stromal p38MAPK/MK2 pathway limits breast cancer metastases and chemotherapy-induced bone loss B Murali, Q Ren, X Luo, DV Faget, C Wang, RM Johnson, T Gruosso, ... Cancer research 78 (19), 5618-5630, 2018 | 62 | 2018 |
| HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells PE Rosenstiel, T Gruosso, AM Letourneau, JJ Chan, A LeBlanc, M Husain, ... Kidney international 74 (8), 1049-1058, 2008 | 61 | 2008 |
| MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas T Gruosso, C Garnier, S Abelanet, Y Kieffer, V Lemesre, D Bellanger, ... Nature communications 6 (1), 1-15, 2015 | 59 | 2015 |
| KIBRA (WWC1) Is a metastasis suppressor gene affected by chromosome 5q loss in triple-negative breast cancer JF Knight, VYC Sung, E Kuzmin, AL Couzens, DA de Verteuil, ... Cell reports 22 (12), 3191-3205, 2018 | 58 | 2018 |
| Ovarian cancer emerging subtypes: role of oxidative stress and fibrosis in tumour development and response to treatment L Batista, T Gruosso, F Mechta-Grigoriou The international journal of biochemistry & cell biology 45 (6), 1092-1098, 2013 | 36 | 2013 |
| Identification of interacting stromal axes in triple-negative breast cancer SMI Saleh, N Bertos, T Gruosso, M Gigoux, M Souleimanova, H Zhao, ... Cancer research 77 (17), 4673-4683, 2017 | 31 | 2017 |
| AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced … TA Yap, NJ Lakhani, DV Araujo, J Rodon Ahnert, SR Chandana, ... Journal of Clinical Oncology 38 (15_suppl), 3587-3587, 2020 | 25 | 2020 |
| The human adenovirus type 5 E4orf4 protein targets two phosphatase regulators of the Hippo signaling pathway MZ Mui, Y Zhou, P Blanchette, N Chughtai, JF Knight, T Gruosso, ... Journal of virology 89 (17), 8855-8870, 2015 | 17 | 2015 |
| THU0329 SAFETY, TARGET ENGAGEMENT, AND INITIAL EFFICACY OF AVID200, A FIRST-IN-CLASS POTENT AND ISOFORM-SELECTIVE INHIBITOR OF TGF-BETA 1 AND 3, IN PATIENTS WITH DIFFUSE … R Lafyatis, R Spiera, R Domsic, A Papazoglou, C Ligon, CMZ Morse, ... Annals of the Rheumatic Diseases 79 (Suppl 1), 390-391, 2020 | 15 | 2020 |
| Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer AH Mohammad, SH Kim, N Bertos, W El-Assaad, I Nandi, H Smith, J Yang, ... Molecular Cancer Research 18 (10), 1477-1490, 2020 | 14 | 2020 |
| P856 AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: results of a phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement … T Yap, D Araujo, D Wood, JF Denis, T Gruosso, G Tremblay, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 1), 2020 | 10 | 2020 |
| Predicting relapse in patients with Triple Negative Breast Cancer (TNBC) using a deep-learning approach G Yu, X Li, TF He, T Gruosso, D Zuo, M Souleimanova, VM Ramos, ... Frontiers in Physiology 11, 2020 | 8 | 2020 |
Morag ParkProfessor of Oncology and Biochemistry, McGill University, Director Goodman Cancer Research Centremcgill.ca의 이메일 확인됨